CA
NZ
UK
AU
IND
US
Allarity Therapeutics, Inc. (NASDAQ: ALLR) concluded the second quarter of 2026 with a solid cash position of $26.9 million, comprising both cash and restricted cash. This figure represents a substantial increase from the previous year's cash total of $14.7 million, enhancing the company's ability …
AnaptysBio (NASDAQ: ANAB) is a clinical‑stage biotechnology firm with aMarket Capitalisationof $1.73 billion, 29,030,784 shares outstanding and $248.47 million in cash. The company reported trailing‑twelve‑month revenue of $232.39 million, a 107.7% increase year‑over‑year, but posted a net margin of -11.5% and aReturn on Equityof …
Achieve Life Sciences, Inc. (NASDAQ: ACHV) has established an at-the-market (ATM) offering program allowing the sale of common stock worth up to $150 million. This initiative was formalized in an agreement with Jefferies LLC and empowers the company to issue shares as needed through …
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) has secured approval from NYSE Regulation for a compliance plan through November 27, 2027, allowing its stock to remain actively traded on the NYSE American. The extension follows a prior notice indicating that Actinium did not meet certain …
argenx SE (NASDAQ: ARGX) announced that its Phase 3 ALKIVIA trial for Vyvgart Hytrulo in autoimmune myositis achieved its primary objective, with the combined IMNM/DM group demonstrating a statistically significant 15.4-point TIS advantage over placebo at 52 weeks.
OmniAb, Inc. (NASDAQ: OABI) shares rose nearly 18% premarket after the company raised its 2026 year-end cash outlook to $49 million to $53 million, up from $37 million to $41 million, following recent technology licensing and business development activity.
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) posted third-quarter results that trailed expectations, with a GAAP net loss of $0.34 per share falling $0.09 short of consensus estimates.
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) completed itsAcquisitionof Azora Therapeutics, shifting focus to AT177, an oral colon-targeted AhR agonist for ulcerative colitis, while closing the first $32 million tranche of up to $64 million in financing.
Quantum BioPharma Ltd. (NASDAQ: QNTM) second-quarter results revealed a fortifiedLiquidityposition, with cash and digital holdings totaling approximately $9.5 million, extending its operational horizon into late 2027.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) reported that its Phase 3 LUGANO trial for DURAVYU in wet age-related macular degeneration missed the primary best-corrected visual acuity endpoint in the full dataset.
Please wait processing your request...